SCHEMBL6420330

SCHEMBL6420330

CO[P](=O)Oc1cccc(-c2nc(=O)c3ccccc3s2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MIF P14174 1/20 0.52
GABRA1 P14867 1/20 0.52
RAB9A P51151 11/20 0.35
ALDH1A1 P00352 11/20 0.35
NPC1 O15118 10/20 0.35
SMN1; SMN2 Q16637 10/20 0.35
NPSR1 Q6W5P4 5/20 0.35
TP53 P04637 3/20 0.35
HSD17B10 Q99714 3/20 0.35
LMNA P02545 2/20 0.35
ALOX15 P16050 2/20 0.35
KDM4E B2RXH2 7/20 0.34
MAPT P10636 5/20 0.34
KMT2A Q03164 4/20 0.34
NFKB1 P19838 3/20 0.34
NFKB2 Q00653 3/20 0.34
RELA Q04206 3/20 0.34
MEN1 O00255 3/20 0.34
RECQL P46063 1/20 0.34
CASP3 P42574 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2956561 0.85 MIF (0.59) MIFGABRA1RAB9AALDH1A1NPC1
SCHEMBL2956514 0.81 MIF (0.54) MIFGABRA1RAB9AALDH1A1NPC1
SCHEMBL2962042 0.79 GABRA1 (0.59) MIFGABRA1RAB9AALDH1A1NPC1
SCHEMBL2957632 0.78 MIF (0.57) MIFGABRA1RAB9AALDH1A1NPC1
SCHEMBL2963185 0.77 GABRA1 (0.56) MIFGABRA1RAB9AALDH1A1NPC1
SCHEMBL2962338 0.75 MIF (0.64) MIFGABRA1RAB9AALDH1A1NPC1
SCHEMBL2959997 0.75 GABRA1 (0.56) MIFGABRA1RAB9AALDH1A1NPC1
SCHEMBL13217133 0.74 MIF (0.56) MIFGABRA1RAB9AALDH1A1NPC1
SCHEMBL2962217 0.74 MIF (0.58) MIFGABRA1RAB9AALDH1A1NPC1
SCHEMBL2955767 0.73 MIF (0.54) MIFGABRA1RAB9AALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032786-A1 1, 3-benzothiazinone derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032786-A1 1, 3-benzothiazinone derivatives and use thereof MIF, MORF4L1, FOXM1 MIF 1/4885GABRA1 3323/4885RAB9A 4678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.